

Neurotech

31 October 2016

FOR RELEASE TO THE MARKET

Ms Anjuli Sinniah
Adviser
Listing Compliance (Perth)
ASX Compliance Pty Ltd
Level 40, Central Park
152 – 158 St Georges Terrace
Perth WA 6000

Dear Ms Sinniah

CONFIRMATION STATEMENT

Neurotech International Ltd (“**Neurotech**” or the “**Company**”) refers to the letter of conditional approval of admission of the Company to the official list of ASX dated 27 October 2016, and advises the following:

Update on manufacturing agreement

As noted in section 10.7 of the Company’s prospectus dated 12 September 2016 (“**Prospectus**”), the Company’s wholly-owned subsidiary, AAT Medical Ltd, entered into a heads of agreement with MCL Components Ltd (“**MCL**”) to manufacture, test and package the Mente product, and to conduct the related sourcing, supplier selection and documentation. A formal agreement has been prepared to replace the heads of agreement but is yet to be executed. Manufacturing has commenced on the first batches of Mente Autism pursuant to the heads of agreement.

Agreement for issue of options to Dr Adrian Attard Trevisan

The Company confirms that the number of options issued to Dr Adrian Attard Trevisan is 1,864,000, as stated on page 127 of the Prospectus. The agreement between the Company and Dr Attard Trevisan with respect to the issue of those options previously referred to the issue of 130,480 options which was a typographical error. That agreement has since been amended to refer to the issue to Dr Attard Trevisan of 1,864,000 options.

Status of distributor agreements

In section 10.3 of the Company’s Prospectus, a number of distributor agreements have expired or are due to expire, being:

- i. Pureline Medical Co. in Saudi Arabia;
- ii. Pureline Medical Co in Bahrain, Oman, Qatar, Kuwait, Jordan and United Arab Emirates;
- iii. A company bearing registration number S-9605 in Iraq; and
- iv. MHT-Group SARL in Lebanon.

As noted in section 3.6 of the Company’s Prospectus, the Company is undertaking a review of these distribution agreements in light of its stated initial focus on target markets in Europe.

Neurotech International Ltd

ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com

The Company anticipates that it will not renew the distributor agreement with respect to Iraq and that the distributor agreement with respect to Lebanon will be renewed for at least one year. The Company is currently determining whether or not it will extend the distributor agreements with Pureline Medical Co. in Saudi Arabia, and Bahrain, Oman, Qatar, Kuwait, Jordan and United Arab Emirates.

Status of patent application PAT/4364

In section 3.8 of the Company's Prospectus, patent PAT/4364 in relation to providing treatment using Cranial Electrotherapy Stimulation ("CES") was noted as currently pending, and yet to be granted. There has been no change in this status to date.

Bank facility status

As noted in section 10.11 of the Company's Prospectus, an aggregate amount of €512,431 remained outstanding with regards to finance facilities with the Bank of Valletta as at 30 August 2016. As at 30 September 2016, an aggregate amount of €646,898 remained outstanding with regard to these facilities.

Sales and marketing commitment

Neurotech confirms that the amount of \$2,104,000 committed for "*Sales and marketing for Mente Autism*" that appears in the use of funds table in section 2.5 of the Company's Prospectus is a commitment that is not dependent or conditional on the successful outcome of the clinical trial in the United States ("**US Clinical Trial**") with respect to Mente Autism.

Neurotech is able to sell its Mente Autism product in the European Union, as Neurotech's existing "CE Marking" is sufficient for sales purposes. The CE Marking shows that Mente Autism complies with European health, safety and environmental protection legislation.

The CE Marking with respect to Mente Autism will decrease the time required to achieve registration of Mente Autism in other markets, including Australia.

In parallel with the already started US Clinical Trial, the company intends to seek to apply for FDA clearance for the Mente Autism device. The US clinical trial will enable Neurotech to make additional claims as to the efficacy of Mente Autism. The ongoing clinical trial and the US FDA clearance will enable Neurotech to apply for the inclusion of Mente Autism for insurance coverage in US.

Yours faithfully,



Fleur Hudson
Company Secretary